Morgenthaler Nils G
From the Institut für Experimentelle Endokrinologie und Endokrinologisches Forschungszentrum, EnForCé, Charité, Berlin, Germany.
Congest Heart Fail. 2010 Jul;16 Suppl 1:S37-44. doi: 10.1111/j.1751-7133.2010.00177.x.
Arginine vasopressin (AVP or antidiuretic hormone) is one of the key hormones in the human body responsible for a variety of cardiovascular and renal functions. It has so far escaped introduction into the routine clinical laboratory due to technical difficulties and preanalytical errors. Copeptin, the C-terminal part of the AVP precursor peptide, was found to be a stable and sensitive surrogate marker for AVP release. Copeptin behaves in a similar manner to mature AVP in the circulation, with respect to osmotic stimuli and hypotension. During the past years, copeptin measurement has been shown to be of interest in a variety of clinical indications, including cardiovascular diseases such as heart failure, myocardial infarction, and stroke. This review summarizes the recent progress on the diagnostic use of copeptin in cardiovascular and renal diseases and discusses the potential use of copeptin measurement in the context of therapeutic interventions with vasopressin receptor antagonists.
精氨酸加压素(AVP,又称抗利尿激素)是人体中负责多种心血管和肾脏功能的关键激素之一。由于技术难题和分析前误差,它至今仍未被引入常规临床实验室。copeptin是AVP前体肽的C末端部分,被发现是AVP释放的一种稳定且敏感的替代标志物。就渗透刺激和低血压而言,copeptin在循环中的行为与成熟的AVP相似。在过去几年中,copeptin检测已显示出在多种临床指征中具有重要意义,包括心力衰竭、心肌梗死和中风等心血管疾病。本综述总结了copeptin在心血管和肾脏疾病诊断应用方面的最新进展,并讨论了在使用血管加压素受体拮抗剂进行治疗干预的背景下copeptin检测的潜在用途。